Fernando Villalta to Drug Design
This is a "connection" page, showing publications Fernando Villalta has written about Drug Design.
Connection Strength
0.360
-
Friggeri L, Hargrove TY, Rachakonda G, Blobaum AL, Fisher P, de Oliveira GM, da Silva CF, Soeiro MNC, Nes WD, Lindsley CW, Villalta F, Guengerich FP, Lepesheva GI. Sterol 14a-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae. J Med Chem. 2018 12 13; 61(23):10910-10921.
Score: 0.149
-
Friggeri L, Hargrove TY, Wawrzak Z, Blobaum AL, Rachakonda G, Lindsley CW, Villalta F, Nes WD, Botta M, Guengerich FP, Lepesheva GI. Sterol 14a-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis. J Med Chem. 2018 07 12; 61(13):5679-5691.
Score: 0.145
-
Friggeri L, Hargrove TY, Rachakonda G, Williams AD, Wawrzak Z, Di Santo R, De Vita D, Waterman MR, Tortorella S, Villalta F, Lepesheva GI. Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14a-demethylase: two regions of the enzyme molecule potentiate its inhibition. J Med Chem. 2014 Aug 14; 57(15):6704-17.
Score: 0.028
-
Lepesheva GI, Park HW, Hargrove TY, Vanhollebeke B, Wawrzak Z, Harp JM, Sundaramoorthy M, Nes WD, Pays E, Chaudhuri M, Villalta F, Waterman MR. Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. J Biol Chem. 2010 Jan 15; 285(3):1773-80.
Score: 0.020
-
Lepesheva GI, Hargrove TY, Kleshchenko Y, Nes WD, Villalta F, Waterman MR. CYP51: A major drug target in the cytochrome P450 superfamily. Lipids. 2008 Dec; 43(12):1117-25.
Score: 0.018